Sadanandan E. Velu, PhD
Dr. Velu is a tenured Professor in the Chemistry Department of University of Alabama at Birmingham. He holds co-appointments as a Scientist at the UAB O’Neal Comprehensive Cancer Center Experimental Therapeutics Program and as an Associate Scientist at the UAB Center for Clinical and Translational Sciences. His research, funded by NIH and AHA focuses on drug discovery and development. His research interests are in the areas of medicinal chemistry, anti-cancer and anti-infective agents, structure based drug design, in-silico screening, directed combinatorial synthesis, structure activity relationship studies, lead optimization and synthesis of marine natural products. He is the author/co-author of >65 peer reviewed research publications and the inventor/co-inventor of 6 issued US/European patents. He serves on the NIH and AHA study sections. He teaches both graduate and undergraduate courses and is a recipient of the National Award for Excellence in Teaching given by the Center for Educational Policy Research, College Board. He currently serves as the Co-Director of the Undergraduate Program in Cancer Biology at UAB.
Chemistry Building 280
Jaden Cowan, Mohammad Shadab, Dwayaja H. Nadkarni, Kailash KC, Sadanandan E. Velu (Co-corresponding author) and Nabiha Yusuf, A Novel Marine Natural Product Derived Pyrroloiminoquinone with Potent Activity against Skin Cancer Cells, Marine Drugs, 17, 1-12 (2019), PubMed PMID: 31357586, PubMed PMCID: NA, DOI: 10.3390/md17080443.
Wei Wang, Jianwen Cheng, Jiang-Jiang Qin, Bo Hu, Xin Li, Bhavitavya Nijampatnam, Sadanandan E Velu, Jia Fan, Xin-Rong Yang, Ruiwen Zhang, MDM2-NFAT1 Dual Inhibitor, MA242: Effective against Hepatocellular Carcinoma, Independent of p53, Cancer Letters (2019), 459: 156-167, PubMed PMID: 31181320, PubMed PMCID: PMC6650270, DOI: 10.1016/j.canlet.2019.114429.
Wei Wang, Jiang-Jiang Qin, Sukesh Voruganti, Bhavitavya Nijampatnam, Sadanandan E. Velu, Ke-He Ruan, Ming Hu, Jianwei Zhou and Ruiwen Zhang, Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy, Cancer Research, 78(19): 5656-5667 (2018). PubMed PMID: 30217928, PMCID: PMC6435280, DOI: 10.1158/0008-5472.CAN-17-3939.
Sandeep Balu Shelar, Eun-Hee Shim, Garrett J. Brinkley, Anirban Kundu, Francesca Carobbio, Tyler Poston, Jubilee Tan, Vishwas Parekh, Daniel Benson, David K. Crossman, Phillip J. Buckhaults, Dinesh Rakheja, Richard Kirkman, Yusuke Sato, Seishi Ogawa, Shilpa Dutta, Sadanandan E. Velu, Ethan Emberley, Alison Pan, Jason Chen, Tony Huang, Devin Absher, Anja Becker, Conrad Kunick, Sunil Sudarshan, Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer, Clinical Cancer Research, 24(24): 6433-6446 (2018). PubMed PMID: 30108105, PubMed PMCID: PMC6295227, DOI: 10.1158/1078-0432.CCR-18-1727.
Bhavitavya Nijampatnam, Hua Zhang,Xia Cai, Suzanne M. Michalek, Hui Wu and Sadanandan E. Velu, Inhibition of Streptococcus mutans Biofilms by the Natural Stilbene Piceatannol Through the Inhibition of Glucosyltransferases, ACS Omega 3 (7), pp 8378–8385 (2018). PubMed PMID: 30087944, PubMedPMCID: PMC6072251, DOI: 10.1021/acsomega.8b00367.
Shilpa Dutta, Samuel Tanner, Frédéric Gradek, Virginie Driffort, Sébastien Roger, Katri Selander and Sadanandan E. Velu (Co-corresponding author), Wayne Brouillette, Discovery and Evaluation of nNav1.5 Sodium Channel Blockers with Potent Cell Invasion Inhibitory Activity in Breast Cancer Cells, Bioorganic and Medicinal Chemistry, 26, 2428-2436 (2018). PubMed PMID: 29673714, PubMed PMCID: PMC5935567, DOI: doi.org/10.1016/j.bmc.2018.04.003.
Jeffrey W. McDonald, John E. Miller, Minjee Kim and Sadanandan E. Velu, An expedient synthesis of murrayaquinone A via a novel oxidative free radical reaction, Tetrahedron Letters, 59, 550-553 (2018). PubMed PMID: 29736091, PubMed PMCID: PMC5935454, DOI: 10.1016/j.tetlet.2018.01.007.